Electra Therapeutics Announces $84 Million Series B Financing And Unveils Its Novel Sirp‑Targeted Therapies For Immunological Diseases And Cancer
Electra Therapeutics Announces $84 Million Series B Financing And Unveils Its Novel Sirp‑Targeted Therapies For Immunological Diseases And Cancer
02/16/22, 12:00 PM
Location
san franciscoMoney raised
$84 million
Round Type
series b
Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies that target signal regulatory proteins (SIRP), announced today a $84 million Series B financing co-led by Westlake Village BioPartners and OrbiMed. Other participating investors include Redmile Group, Cormorant Asset Management, Cowen Healthcare Investments, RA Capital, and New Leaf Venture Partners. Electra was previously funded by its parent company, Star Therapeutics.
Company Info
Location
san francisco, california, united states
Additional Info
Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Electra currently has one program in clinical development and two additional preclinical programs. The company’s lead product candidate, ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells, and depletes pathological immune cells. ELA026 is in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening hyperinflammatory condition for which there is no approved treatment. For more information, please visit Electra Therapeutics and follow us on Twitter @ELECTRA_Biotech and LinkedIn.